THC Biomed Intl Ltd. (THCBF)

[cuckoo 4 cocoa puffs]

THC Closes Non-Brokered Private Placement of Convertible Debentures
THC.CSE THCBF - OTC TFHC.F
Vancouver, B.C. – (August 16, 2019) THC BioMed Intl Ltd. (CSE: THC), ("THC" or the
"Company") announces it has closed a non-brokered private placement of convertible
debentures for gross proceeds of $642,679.09 (the “Debenture”). Dated August 16, 2019, the
term of the Debenture is 12 months and bears interest at 8% per annum calculated on an annual
basis and payable semi-annually in arrears. The Debenture is convertible into common shares at
a price of $0.25 per share, at any time at the election of the holder.
The proceeds of the Debenture will be used by the Company towards funding the continuous
growth and expansion of the Company as well as general working capital.
About THC
THC's vision is to be on the leading edge of scientific research, development of products and
services related to the medical cannabis industry while creating a standard of excellence. As the
industry develops, it will become more important to focus on scientific research and development
of products and services related to medical cannabis. Management believes THC is wellpositioned to be in the forefront of this rapidly growing industry.
Please visit our website for a more detailed description of our business and services available.
www.thcbiomed.com
President and CEO:
John Miller
THC Biomed Intl Ltd.
T: 1-844-THCMEDS
E: [e-mail]
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the


https://webfiles.thecse.com/sedar_filings/00005612/1908161434406495.pdf